Screening for hepatitis B virus infection among refugees diagnosed with latent tuberculosis in an Italian community
Keywords:
Chemoprophylaxis, co-infection, hepatitis B virus infection, latent tuberculosis infection, refugees, screeningAbstract
Background. Refugees are a growing population in the EU-27 area with specific health needs that are to be addressed in the most rapid and effective way at their arrival in the host country. Screening for Hepatitis B Virus infection is offered to specific categories and it could be useful and effective to extend its indications. The aim of this study was to define the epidemiological profile regarding Hepatitis B Virus infection in refugees hosted in the Asylum Seekers Centers of Verona (Italy), diagnosed with latent tuberculosis infection and eligible for chemoprophylaxis.
Methods. We conducted a retrospective study in 715 refugees diagnosed with latent tuberculosis infection from January 1st, 2015 to December 31st, 2017. Screening for Hepatitis B Virus infection was offered to latent tuberculosis infection patients who were due to commence treatment. Subjects were tested for Hepatitis B surface Antigen and Hepatitis B core antigen total antibodies. None of the screened patients reported previous vaccination for hepatitis B.
Results. Among the 715 refugees diagnosed with latent tuberculosis infection, 593 were eligible for treatment for latent tuberculosis infection. Of these, 211 (35.6%) accepted to be screened for Hepatitis B Virus infection. One hundred and ninety-five of the 211 (92.4%) came from African countries, and 16 (7.6%) from Asia; the majority (80.9%) were males. Median age was 23 years (95% CI 22-24). Of the 211, 58 individuals (27.5%) were Hepatitis B surface Antigen and Hepatitis B core antigen total antibodies positive; 74 (35.1%) were Hepatitis B surface Antigen negative and Hepatitis B core antigen total antibodies positive; and 79 (37.4%) were Hepatitis B surface Antigen and Hepatitis B core antigen total antibodies negative. Male gender and African origin were associated with a lower probability of being Hepatitis B surface Antigen- and Hepatitis B core antigen total antibodies-negative.
Conclusions. Screening for Hepatitis B Virus is of paramount importance not only for the control and prevention of infection, but also in terms of long-term healthcare issues. Making screening more systematic can have an important impact on public health, while always considering cost-effectiveness and promotion of awareness among ethnic groups in order to gain their compliance to treatment/vaccination.
References
1. Italian Ministry of Interns. Arrivals and reception of migrants: all the data. 22th January 2021. Available on: https://www.interno.gov.it/ it/stampa-e-comunicazione/dati-e-statistiche/ sbarchi-e-accoglienza-dei-migranti-tutti-i-dati [Last accessed: 2021 Jan 24].
2. UN to governments: protection for climate emergency refugees. 21th January 2020. Available on: https://www.ilsole24ore.com/art/l-onu-governiprotezione-rifugiati-dell-emergenza-climaticaAC8OfKDB?refresh_ce=1 [Last accessed: 2021 Jan 24].
3. Eurostat. Asylum statistics. 1st September 2020 Available on: https://ec.europa.eu/eurostat/ statistics-explained/index.php?title=Asylum_ statistics/it#Aumento_del_numero_di_richiedenti_asilo_nel_2019 [Last accessed: 2021 Jan 24].
4. Italian Ministry of Interns. Data from the National Asylum Commission. 20th June 2020. Available on: https://www.interno.gov.it/it/ notizie/giornata-mondiale-rifugiato-2020-quasi11mila-richieste-asilo-presentate-questanno [Last accessed: 2021 Jan 24].
5. European Center for Disease Prevention and Control (ECDC). Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/ EEA. ECDC, 2018. Available on: https://www. ecdc.europa.eu/sites/portal/files/documents/ Public%20health%20guidance%20on%20 screening%20and%20vaccination%20of%20 migrants%20in%20the%20EU%20EEA.pdf
[Last accessed: 2021 Jan 24].
6. National System for Guidelines (Italy). Controls at the border. Border of controls. Health checks on arrival and protection paths for migrants hosted in reception centers. Available on: http:// www.inmp.it/lg/LG_Migranti-integrata.pdf [Last accessed: 2021 Jan 24].
7. Sulis G, Roggi A, Matteelli A, Raviglione MC. Tuberculosis: Epidemiology and control. Mediterr J Hematol Infect Dis 2014; 6(1): e2014070. doi: 10.4084/mjhid.2014.070.
8. World Health Organization (WHO). Global health sector strategy on viral hepatitis 20162021. Available on: https://www.who.int/ hepatitis/strategy2016-2021/ghss-hep/en [Last accessed: 2021 Jan 24].
9. Bordin P, Gazzani D, Postiglione C, et al. Latent tuberculosis infection cascade of care among asylum seekers in Verona, Italy. Journal of Health Care for the Poor and Underserved, 2021 (In press).
10. Person AK, Pettit AC, Sterling TR. Diagnosis and treatment of latent tuberculosis infection: an update. Curr Respir Care Rep 2013; 2(4): 199-207. doi: 10.1007/s13665-013-0064-y.
11. Khyatti M, Trimbitas RD, Zouheir Y, Benani A, El Messaoudi MD, Hemminki K. Infectious diseases in North Africa and North African immigrants to Europe. Eur J Public Health 2014; 24(Suppl 1): 47-56. doi: 10.1093/eurpub/ cku109. PMID: 25107998.
12. European Centre for Disease Prevention and Control (ECDC)/ World Health Organization (WHO). Tuberculosis surveillance and monitoring in Europe 2019. Copenhagen: WHO Regional Office for Europe, 2019.
Available on: https://www.ecdc.europa.eu/sites/ portal/files/documents/tuberculosis-surveillance-monitoring-Europe-2019-20_Mar_2019. pdf [Last accessed: 2021 Jan 24].
13. D’Amato S, Bonfigli S, Cenci C, Maraglino FP. Tuberculosis among foreigners in Italy. In: Osservasalute Report 2016. Health status and quality of care in Italian regions. Available on: https://www.osservatoriosullasalute. it/wp-content/uploads/2017/03/ro-2016-argpopolazione_straniera.pdf [Last accessed: 2021 Jan 24].
14. Abarca Tomás B, Pell C, Bueno Cavanillas A, Guillén Solvas J, Pool R, Roura M. Tuberculosis in migrant populations. A systematic review of the qualitative literature. PLoS One 2013; 8(12):
e82440. doi: 10.1371/journal.pone.0082440.
15. World Health Organization (WHO). Systematic screening for active tuberculosis. Principles and recommendations. Geneva: WHO, 2012. Available on: https://www.who.int/tb/tbscreening/en [Last accessed: 2021 Jan 24].
16. Italian Ministry of Labour, Health and Social Policy. Effective policies to contrast tuberculosis in immigrants from high TB endemic countries. Available on: https://www.saluteinternazionale.info/2010/03/politiche-efficaci-percontrastare-la-tubercolosi-negli-immigrati-leraccomandazioni-degli-esperti [Last accessed: 2021 Jan 24].
17. Klinkenberg E, Manissero D, Semenza JC, Verver S. Migrant tuberculosis screening in the EU/EEA: yield, coverage and limitations. Eur Respir J 2009; 34(5): 1180-9. doi: 10.1183/09031936.00038009.
18. Taylor Z, Nolan CM, Blumberg HM; American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep 2005; 54(RR-12): 1-81. Erratum in: MMWR Morb Mortal Wkly Rep 2005; 54(45): 1161.
19. European Centre for Disease Prevention and Control (ECDC). Epidemiological assessment of hepatitis B and C among migrants in the EU/ EEA. Stockholm: ECDC, 2016.
Available on: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/ epidemiological-assessment-hepatitis-B-andCamong-migrants-EU-EEA.pdf [Last accessed: 2021 Jan 24].
20. Tosti ME, Mele A, Spada E, et al. and SEIEVA Collaboration Group. X SEIEVA Workshop (Sistema Epidemiologico Integrato dell’Epidemiologico dell’Epatite Virale Acuta). Bagno Vignoni (SI) 13-15 December 2012. ISTISAN Reports 15/29 2015. Available on: https:// www.iss.it/documents/20126/45616/15_29_ web.pdf/7ecfb734-b881-9d00-c56a-0c2883b42258?t=1581099103022 [Last accessed: 2021 Jan 14].
21. Tosti ME, Alfonsi V, Baglio G. Acute viral hepatitis among foreigners. In: Osservasalute Report 2014. Health status and quality of care in the Italian regions. Milan: Prex Ed., 2015: 303-9.
22. Rossi C, Shrier I, Marshall L, et al. Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: a systematic review and meta-analysis. PLoS One 2012; 7(9): e44611. doi: 10.1371/journal.
pone.0044611. Epub 2012 Sep 5.
23. Scotto G, Fazio V, Lo Muzio L, Coppola N. Screening for infectious diseases in newly arrived asymptomatic immigrants in southern Italy. East Mediterr Health J 2019; 25(4): 246-53. https://doi.org/10.26719/emhj.18.035.
24. Cuomo G, Franconi I, Riva N, et al. Migration and health: A retrospective study about the prevalence of HBV, HIV, HCV, tuberculosis and syphilis infections amongst newly arrived migrants screened at the Infectious Diseases Unit of Modena, Italy. J Infect Public Health 2019; 12(2): 200-204. doi: 10.1016/j.jiph.2018.10.004. Epub 2018 Oct 28.
25. Padovese V, Egidi AM, Melillo TF, et al. Prevalence of latent tuberculosis, syphilis, hepatitis B and C among asylum seekers in Malta. J Public Health (Oxf) 2014; 36(1): 22-7. doi: 10.1093/ pubmed/fdt036. Epub 2013 Apr 4.
26. Tafuri S, Prato R, Martinelli D, et al. Prevalence of Hepatitis B, C, HIV and syphilis markers among refugees in Bari, Italy. BMC Infect Dis 2010; 10: 213. doi: 10.1186/1471-2334-10-213.
27. Buonfrate D, Gobbi F, Marchese V, et al. Extended screening for infectious diseases among newly-arrived asylum seekers from Africa and Asia, Verona province, Italy, April 2014 to June 2015. Euro Surveill 2018; 23(16): 17-00527. doi: 10.2807/1560-7917.ES.2018.23.16.17-00527.
28. Nooredinvand HA, Connell DW, Asgheddi M, et al. Viral hepatitis prevalence in patients with active and latent tuberculosis. World J Gastroenterol 2015; 21(29): 8920-6. doi: 10.3748/wjg. v21.i29.8920.
29. Kuniholm MH, Mark J, Aladashvili M, et al. Risk factors and algorithms to identify hepatitis C, hepatitis B, and HIV among Georgian tuberculosis patients. Int J Infect Dis 2008; 12(1): 51-6. doi: 10.1016/j.ijid.2007.04.015. Epub 2007 Jul 23.
30. Blal CA, Passos SR, Horn C, et al. High prevalence of hepatitis B virus infection among tuberculosis patients with and without HIV in Rio de Janeiro, Brazil. Eur J Clin Microbiol Infect Dis 2005; 24(1): 41-3. doi: 10.1007/s10096-0041272-8.
31. Sirinak C, Kittikraisak W, Pinjeesekikul D, et al. Viral hepatitis and HIV-associated tuberculosis: risk factors and TB treatment outcomes in Thailand. BMC Public Health 2008; 8: 245. doi:
10.1186/1471-2458-8-245.
32. Aires RS, Matos MA, Lopes CL, et al. Prevalence of hepatitis B virus infection among tuberculosis patients with or without HIV in Goiânia City, Brazil. J Clin Virol 2012; 54(4): 327-31. doi: 10.1016/j.jcv.2012.04.006. Epub 2012 May 18.
33. Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol 2008; 14(44): 6774-85. doi: 10.3748/wjg.14.6774.
34. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008; 23(2): 192-202. doi: 10.1111/j.14401746.2007.05207.x. Epub 2007 Nov 6.
35. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167(11): 1472-7. doi: 10.1164/rccm.200206-626OC. Epub 2003 Jan 31.
36. Chien JY, Huang RM, Wang JY, et al. Hepatitis C virus infection increases hepatitis risk during antituberculosis treatment. Int J Tuberc Lung Dis 2010; 14(5): 616-21.
37. Patel PA, Voigt MD. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol 2002; 97(5): 1198-203. doi: 10.1111/j.1572-0241.2002.05704.x.
38. de Castro L, do Brasil PE, Monteiro TP, Rolla VC. Can hepatitis B virus infection predict tuberculosis treatment liver toxicity? Development of a preliminary prediction rule. Int J Tuberc Lung Dis 2010; 14(3): 332-40.
39. Lee BH, Koh WJ, Choi MS, et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005; 127(4): 1304-11. doi: 10.1378/ chest.127.4.1304.
40. Nader LA, de Mattos AA, Picon PD, Bassanesi SL, De Mattos AZ, Pineiro Rodriguez M. Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor? Ann Hepatol 2010; 9(1): 70-4.
41. Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157(6 Pt 1): 1871-6. doi: 10.1164/ ajrccm.157.6.9711039.
42. Chen L, Bao D, Gu L, Zhou L, Gao Z, Huang Y. Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment. BMC Infect Dis 2018; 18(1): 295. doi: 10.1186/ s12879-018-3192-8.
43. Migrant Health Assessment, Sub-committee of Health Protection Surveillance Centre, Scientific Advisory Committee, 2015. Infectious Disease Assessment for Migrants. Available on: https:// www.hpsc.ie/a-z/specificpopulations/migrants/ guidance/File,14742,en.pdf [Last accessed: 2021 Jan 24].
44. Almasio PL, Babudieri S, Barbarini G, et al. Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates). Dig Liver Dis 2011; 43(8): 589-95. doi: 10.1016/j.dld.2010.12.004. Epub 2011 Jan 21.
45. National Institute for Health and Care Excellence. Hepatitis B and C: ways to promote and offer testing to people at increased risk of infection. Available on: https://www.nice.org. uk/guidance/ph43/resources/hepatitis-b-andc-ways-to-promote-and-offer-testing-draftguidance2 [Last accessed: 2021 Jan 24].
46. Ministry of Health of Singapore. Chronic Hepatitis B Infection: MOH Clinical Practice Guidelines 2/2011. Available on: https://www. moh.gov.sg/docs/librariesprovider4/guidelines/ cpg-chronic-hep-b-infection---mar-2011.pdf [Last accessed: 2021 Jan 24].
47. Weinbaum CM, Mast EE, Ward JW. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology 2009; 49(5 Suppl): S35-44. doi: 10.1002/hep.22882.
48. Chaves NJ, Paxton G, Biggs BA, et al. on behalf of the Australasian Society for Infectious Disease and Refugee Health Network of Australia. Recommendations for comprehensive post-arrival health assessment for people from refugee-like backgrounds. 2nd ed. 2016. Available on: https://www.asid.net.au/documents/ item/1225 [Last accessed: 2021 Jan 24].
49. National Center for Emerging and Zoonotic Infectious Diseases/Center for Disease, Control and Prevention. Screening for hepatitis during the domestic medical examination for newly arrived refugees. 26th November 2018. Available on: https://www.cdc.gov/immigrantrefugeehealth/guidelines/domestic/hepatitis-screeningguidelines.html [Last accessed: 2021 Jan 24].
50. Coffin CS, Fung SK, Ma MM. Canadian Association for the Study of the Liver. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012; 26(12): 917-38. doi:
10.1155/2012/506819.
51. Pottie K, Greenaway C, Feightner J, et al. Evidence-based clinical guidelines for immigrants and refugee. CMAJ 2011; 183(12): E824-925.
doi: 10.1503/cmaj.090313. Epub 2010 Jun 7.
52. Do TN, Nam S. Knowledge, Awareness and Medical Practice of Asian Americans/Pacific Islanders on Chronic Hepatitis B Infection: Review of Current Psychosocial Evidence. Pogon Sahoe Yongu 2011; 31(3): 341-64. doi: 10.15709/hswr.2011.31.3.341.
53. Owiti JA, Greenhalgh T, Sweeney L, Foster GR, Bhui KS. Illness perceptions and explanatory models of viral hepatitis B & C among immigrants and refugees: a narrative systematic review. BMC Public Health 2015; 15: 151. doi: 10.1186/s12889-015-1476-0.
54. Lee A, Vedio A, Lio EZH, et al. Determinants of uptake of heptitis B testing and healthcare access by migrant Chinese in England: a qualitative study. BMC Public Health 2017; 17(1): 747. doi: 10.1186/s12889-017-4796-4.
55. Hargreaves S, Seedat F, Car J, et al. Screening for latent TB, HIV, and hepatitis B/C in new migrants in a high prevalence area of London, UK: a cross-sectional study. BMC Infect Dis 2014; 14: 657. doi: 10.1186/s12879-014-0657-2.
56. World Health Organization (WHO). Immunization coverage. Available on: https://www.who. int/immunization/monitoring_surveillance/ routine/coverage/en/
57. World Health Organization. Global Hepatitis Report 2017. Available on: http://apps.who.int/ iris/bitstream/10665/255016/1/978924156545 5-eng.pdf?ua=1 [Last accessed: 2021 Jan 24].
58. Seedat F, Hargreaves S, Nellums LB, Ouyang J, Brown M, Friedland JSl. How effective are approaches to migrant screening for infectious diseases in Europe? A systematic review. Lancet Infect Dis 2018; 18(9): e259-e271. doi: 10.1016/S1473-3099(18)30117-8. Epub 2018 May 16.
59. Petersen E. Should we offer screening for hepatitis B and other infections to immigrants-legal
or illegal? J Travel Med 2015; 22(2): 73-5. doi: 10.1111/jtm.12188.
60. Veldhuijzen IK, Toy M, Hahné SJ, De Wit GA, Schalm SW, de Man RA, Richardus JH. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology 2010; 138(2): 522-30. doi: 10.1053/j. gastro.2009.10.039. Epub 2009 Oct 29.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.